Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response

BACKGROUND/AIMS: Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus tenofovir (ETV+TDF) to those maintained on LAM/LdT+ADV. METHODS:...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Mol Hepatol
Hlavní autoři: Woo, Hyun Young, Park, Jun Yong, Bae, Si Hyun, Kim, Chang Wook, Jang, Jae Young, Tak, Won Young, Kim, Dong Joon, Kim, In Hee, Heo, Jeong, Ahn, Sang Hoon
Médium: Artigo
Jazyk:Inglês
Vydáno: The Korean Association for the Study of the Liver 2020
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7364362/
https://ncbi.nlm.nih.gov/pubmed/32460460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2019.0044n
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky